Strategies Combining Nivolumab Show Promise for Classic Hodgkin Lymphoma
Researchers found that 2 studied strategies, which combined nivolumab and doxorubicin, vinblastine, and dacarbazine, are feasible, highly effective, and result in excellent 12-month progression-free survival.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
More News: Cancer & Oncology | Lymphoma